- Home
- HROW vs SGHC Comparison
HROW vs SGHC Comparison
Compare HROW & SGHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HROW | SGHC |
|---|---|---|
| Founded | 1998 | 2020 |
| Country | United States | Guernsey |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Services-Misc. Amusement & Recreation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 7.1B |
| IPO Year | 2008 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HROW | SGHC |
|---|---|---|
| Price | $33.73 | $13.34 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 6 |
| Target Price | ★ $69.86 | $17.33 |
| AVG Volume (30 Days) | 426.1K | ★ 2.1M |
| Earning Date | 05-11-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 3.52% |
| EPS Growth | ★ 71.43 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $31.62 | $16.09 |
| Revenue Next Year | $50.77 | $9.73 |
| P/E Ratio | ★ N/A | $20.80 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $28.54 | $8.46 |
| 52 Week High | $54.98 | $15.86 |
Technical Indicators
Market Signals| Indicator | HROW | SGHC |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 44.88 |
| Support Level | $32.74 | $13.23 |
| Resistance Level | $36.37 | $14.22 |
| Average True Range (ATR) | 1.33 | 0.39 |
| MACD | -0.44 | -0.02 |
| Stochastic Oscillator | 21.33 | 13.79 |
Price Performance
Historical ComparisonAbout HROW Harrow Inc.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
About SGHC Super Group (SGHC) Limited
Super Group (SGHC) Ltd is a holding company that operates online sports betting and gaming businesses. The company's four operating segments-Betway, Spin, Jumpman and DGC. A majority of its revenue is generated from the Betway segment, which is a single-brand online sports betting and casino offering with licenses to operate throughout Europe, the Americas, and Africa. Spin is the company's multi-brand online casino offering, having a diverse portfolio of casino brands such as Jackpot City, Spin Casino, Dream Bingo, Mirror Bingo, etc., designed to be culturally relevant globally while aiming to offer a wide range of casino products. Geographically, the company generates maximum revenue from Africa and Middle East, followed by North America, Europe, Asia-Pacific, and South/Latin America.